Emerging therapies for malignant glioma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Malignant gliomas are typically treated with surgery, radiotherapy, and conventional chemotherapy.
• These standard treatments lack specificity and can cause significant toxicity.
• Advances in molecular biology enable the development of targeted therapies for specific cancer pathways.

Purpose of the Study:

• To review the potential of targeted therapies in treating malignant gliomas.
• To focus on signal transduction inhibitors and their mechanisms.
• To discuss inhibitors of tyrosine kinases, targets of rapamycin, farnesyl transferase, histone deacetylase, and angiogenesis.

Main Methods:

• Literature review of targeted therapies for malignant gliomas.
• Focus on agents affecting signal transduction pathways.
• Discussion of various classes of molecularly targeted agents.

Main Results:

• Targeted therapies aim to increase efficacy and reduce toxicity by targeting specific molecular pathways.
• Inhibitors of tyrosine kinases, mTOR, farnesyl transferase, and histone deacetylase show potential.
• Angiogenesis inhibitors are also being investigated for glioma treatment.

Conclusions:

• Targeted therapies represent a shift towards personalized medicine in oncology.
• These agents offer the potential for more effective and less toxic treatments for malignant gliomas.
• Understanding complex interactions between targeted therapies is crucial for clinical application.